{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-007491","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.647106+00:00","generated_at":"2026-05-16T02:55:49.950086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability","bullets":["Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.","GAAP net income $111.5M ($0.82 diluted EPS) vs. loss a year ago; full-year GAAP net income $313.7M.","Non-GAAP operating income $849.8M for FY2025; company expects sustainable operating income growth.","AMVUTTRA (ATTR-CM) drove TTR franchise: Q4 $827M, full year $2,314M (+103% YoY).","Launches 'Alnylam 2030' strategy; plans $250M manufacturing expansion; board appoints Stuart Arbuckle."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-007491","json":"https://secwatch.observer/filing/0001628280-26-007491.json","markdown":"https://secwatch.observer/filing/0001628280-26-007491.md","text":"https://secwatch.observer/filing/0001628280-26-007491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/0001628280-26-007491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026007491/alny-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:55:49.950086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}